Management of pheochromocytomas and paragangliomas: Review of
current diagnosis and treatment options

J 2023

Management of pheochromocytomas and paragangliomas: Review of current diagnosis and treatment options

EID, Michal, Jakub FOUKAL, Dana SOCHOROVÁ, Štěpán TUČEK, Karel STARÝ et. al.

Basic information

Original name

Management of pheochromocytomas and paragangliomas: Review of current diagnosis and treatment options

Authors

EID, Michal (203 Czech Republic, belonging to the institution), Jakub FOUKAL (203 Czech Republic, belonging to the institution), Dana SOCHOROVÁ (203 Czech Republic, belonging to the institution), Štěpán TUČEK (203 Czech Republic, belonging to the institution), Karel STARÝ (203 Czech Republic, belonging to the institution), Zdeněk KALA (203 Czech Republic, belonging to the institution), Jiří MAYER (203 Czech Republic, belonging to the institution), Radim NĚMEČEK (203 Czech Republic, belonging to the institution), Jan TRNA (203 Czech Republic, belonging to the institution) and Lumír KUNOVSKÝ (203 Czech Republic, guarantor, belonging to the institution)

Edition

Cancer Medicine, Hoboken, John Wiley & Sons Ltd. 2023, 2045-7634

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 4.000 in 2022

RIV identification code

RIV/00216224:14110/23:00130968

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1002/cam4.6010

UT WoS

000981618600001

Keywords in English

biomarkers; chemotherapy; molecular biology; prognostic factor; surgery; target therapy

Abstract

V originále

Pheochromocytomas (PCCs) are rare neuroendocrine tumors derived from the chromaffin cells of the adrenal medulla. When these tumors have an extra-adrenal location, they are called paragangliomas (PGLs) and arise from sympathetic and parasympathetic ganglia, particularly of the para-aortic location. Up to 25% of PCCs/PGLs are associated with inherited genetic disorders. The majority of PCCs/PGLs exhibit indolent behavior. However, according to their affiliation to molecular clusters based on underlying genetic aberrations, their tumorigenesis, location, clinical symptomatology, and potential to metastasize are heterogenous. Thus, PCCs/PGLs are often associated with diagnostic difficulties. In recent years, extensive research revealed a broad genetic background and multiple signaling pathways leading to tumor development. Along with this, the diagnostic and therapeutic options were also expanded. In this review, we focus on the current knowledge and recent advancements in the diagnosis and treatment of PCCs/PGLs with respect to the underlying gene alterations while also discussing future perspectives in this field.

Links

MUNI/A/1224/2022, interní kód MU

Name: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit X

Investor: Masaryk University

Citovat

EID, Michal, Jakub FOUKAL, Dana SOCHOROVÁ, Štěpán TUČEK, Karel STARÝ, Zdeněk KALA, Jiří MAYER, Radim NĚMEČEK, Jan TRNA and Lumír KUNOVSKÝ. Management of pheochromocytomas and paragangliomas: Review of current diagnosis and treatment options. Cancer Medicine. Hoboken: John Wiley & Sons Ltd., 2023, vol. 12, No 13, p. 13942-13957. ISSN 2045-7634. Available from: https://dx.doi.org/10.1002/cam4.6010.

@article{2291626,
   author = {Eid, Michal and Foukal, Jakub and Sochorová, Dana and Tuček, Štěpán and Starý, Karel and Kala, Zdeněk and Mayer, Jiří and Němeček, Radim and Trna, Jan and Kunovský, Lumír},
   article_location = {Hoboken},
   article_number = {13},
   doi = {http://dx.doi.org/10.1002/cam4.6010},
   keywords = {biomarkers; chemotherapy; molecular biology; prognostic factor; surgery; target therapy},
   language = {eng},
   issn = {2045-7634},
   journal = {Cancer Medicine},
   title = {Management of pheochromocytomas and paragangliomas: Review of current diagnosis and treatment options},
   url = {https://onlinelibrary.wiley.com/doi/10.1002/cam4.6010},
   volume = {12},
   year = {2023}
}

TY  - JOUR
ID  - 2291626
AU  - Eid, Michal - Foukal, Jakub - Sochorová, Dana - Tuček, Štěpán - Starý, Karel - Kala, Zdeněk - Mayer, Jiří - Němeček, Radim - Trna, Jan - Kunovský, Lumír
PY  - 2023
TI  - Management of pheochromocytomas and paragangliomas: Review of current diagnosis and treatment options
JF  - Cancer Medicine
VL  - 12
IS  - 13
SP  - 13942-13957
EP  - 13942-13957
PB  - John Wiley & Sons Ltd.
SN  - 20457634
KW  - biomarkers
KW  - chemotherapy
KW  - molecular biology
KW  - prognostic factor
KW  - surgery
KW  - target therapy
UR  - https://onlinelibrary.wiley.com/doi/10.1002/cam4.6010
N2  - Pheochromocytomas (PCCs) are rare neuroendocrine tumors derived from the chromaffin cells of the adrenal medulla. When these tumors have an extra-adrenal location, they are called paragangliomas (PGLs) and arise from sympathetic and parasympathetic ganglia, particularly of the para-aortic location. Up to 25% of PCCs/PGLs are associated with inherited genetic disorders. The majority of PCCs/PGLs exhibit indolent behavior. However, according to their affiliation to molecular clusters based on underlying genetic aberrations, their tumorigenesis, location, clinical symptomatology, and potential to metastasize are heterogenous. Thus, PCCs/PGLs are often associated with diagnostic difficulties. In recent years, extensive research revealed a broad genetic background and multiple signaling pathways leading to tumor development. Along with this, the diagnostic and therapeutic options were also expanded. In this review, we focus on the current knowledge and recent advancements in the diagnosis and treatment of PCCs/PGLs with respect to the underlying gene alterations while also discussing future perspectives in this field.
ER  -

EID, Michal, Jakub FOUKAL, Dana SOCHOROVÁ, Štěpán TUČEK, Karel STARÝ, Zdeněk KALA, Jiří MAYER, Radim NĚMEČEK, Jan TRNA and Lumír KUNOVSKÝ. Management of pheochromocytomas and paragangliomas: Review of current diagnosis and treatment options. \textit{Cancer Medicine}. Hoboken: John Wiley \&{} Sons Ltd., 2023, vol.~12, No~13, p.~13942-13957. ISSN~2045-7634. Available from: https://dx.doi.org/10.1002/cam4.6010.

Detailed Information on Publication Record